Differential diagnosis of thyroid nodules using fine-needle aspiration cytology and oncogene mutation screening: are we ready? by Melillo, Rosa Marina et al.
Differential diagnosis of thyroid nodules using fine-needle aspiration
cytology and oncogene mutation screening: are we ready?
Rosa Marina Melillo
1,2, Massimo Santoro
1 and Giancarlo Vecchio
1*
Addresses:
1Dipartimento di Biologia e Patologia Cellulare e Molecolare ‘L. Califano’ (DBPCM), University of Naples Federico II, Via S. Pansini, 5,
80131 Naples, Italy;
2Istituto per l’Endocrinologia e l’Oncologia Sperimentale del CNR ‘G. Salvatore’ (IEOS), Via S. Pansini, 5, 80131 Naples, Italy
*Corresponding author: Giancarlo Vecchio (vecchio@unina.it)
F1000 Medicine Reports 2010, 2:62 (doi:10.3410/M2-62)
The electronic version of this article is the complete one and can be found at: http://f1000.com/reports/medicine/content/2/62
Abstract
Thyroid nodules are a very common clinical finding, and although the majority of them are benign,
thyroid carcinoma accounts for about 5-15% of nodules. Fine-needle aspiration cytology (FNAC) is
actually used for the differential diagnosis of these lesions. Although in most cases this examination
clearly distinguishes benign from malignant lesions, some fine-needle aspiration (FNA) samples fall
into undetermined thyroid cytology categories, which according to the most recent classification of
thyroid FNAC consist of ‘suspicious for malignancy’, ‘suspicious for follicular or Hurtle cell
neoplasm’, and ‘follicular lesion of undetermined significance/atypia of undetermined significance’.
Moreover, some samples are insufficient for diagnosis. Taken together, these categories account for
almost 20-30% of nodules. Owing to the high risk of papillary thyroid carcinoma, patients with lesions
that are ‘suspicious for malignancy’ are currently subjected to lobectomy or total thyroidectomy. On
the other hand, patients with ‘atypia of undetermined significance’ undergo repeated FNAs, and
patients with ‘suspicious for follicular or Hurtle cell neoplasm’ are subjected to diagnostic lobectomy
and subsequently, in the case of histological diagnosis of carcinoma, total thyroidectomy. Recent
studies clearly indicate that molecular analysis of thyroid nodules can significantly improve the
diagnostic power of cytology and drive the appropriate clinical management of these patients.
Introduction and context
The incidence of thyroid nodules detected by clinical
examination or by ultrasonography is very high in the
adult population. For establishing whether these lesions
are benign or malignant, fine-needle aspiration cytology
(FNAC) is currently the gold standard. Prior to the
routine use of thyroid fine-needle aspiration (FNA), only
14% of surgically resected thyroid nodules were found
to be malignant [1]. With current thyroid FNA practice,
greater than 50% of resected nodules are malignant [2].
Benign lesions identified by FNAC are generally left
untreated, but patients undergo periodic clinical and
ultrasound examination. Patients with malignant
nodules undergo total thyroidectomy. However, FNAC
is hampered by some limitations. First, some FNA
samples (non-diagnostic) are simply insufficient for the
diagnosis because they contain only cystic fluid or scant
material, and this requires that patients’ repeat FNA with
ultrasound guide. Second, some FNACs reveal lesions of
uncertain nature. These lesions have been classified
according to the suggested thyroid FNA classification
scheme of the National Cancer Institute [3] using the
following categories: ‘suspicious for malignancy’, ‘suspi-
cious for follicular neoplasm’, ‘suspicious for Hurtle cell
neoplasm’, and ‘[follicular] lesions of undetermined
significance (FLUSs)/atypia of undetermined signifi-
cance’.T h e‘suspicious for malignancy’ category includes
entities for which the evidence for malignancy is not
definitive. It represents 3-9% of all thyroid FNA results,
and between 60-77% of these cases prove to be
malignant (mainly papillary thyroid carcinoma, or
PTC) [2,4-6]. The ‘suspicious for follicular cell neoplasm’
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with significant architectural atypia and follicular pro-
liferation. These lesions include follicular adenoma (FA),
follicular thyroid carcinoma (FTC), and follicular variant
of PTC (fvPTC). Because it is not possible to identify
capsular or vascular invasion (considered to be the
hallmarks of FTC), a definitive diagnosis of follicular
carcinoma by FNA cannot be made. For this reason,
patients who present with these features must undergo
diagnostic lobectomy. The malignancy rate for these
cases ranges from 14% to 32% [2,4-6]. The ‘suspicious
for Hurtle cell neoplasm’ category also includes Hurtle
cell carcinoma and Hurtle cell adenoma, for which the
differential diagnosis on the basis of FNAC is not
possible and hence a diagnostic lobectomy is necessary.
Finally, the FLUS group includes cases that do not fit into
any of the other categories. The malignancy rate
(approximately 5-10%) of these lesions is not sufficient
to justify immediate surgery, and the recommended
treatment is repeated FNAs. Taken together, these studies
indicate that, although FNAC is the gold standard for the
differential diagnosis of thyroid nodules, this technique
has some limitations, and a certain number of lesions
remain undefined. The discovery of specific genetic
lesions in different histotypes of human thyroid cancer
has raised the possibility of improving the diagnostic
accuracy of FNAC. Thyroid cancer, though a rare disease,
is the most frequent endocrine neoplasia and its
incidence is rapidly increasing. Three malignant lesions
derive from follicular cells: well-differentiated thyroid
carcinomas (which include PTC and FTC), poorly
differentiated thyroid carcinomas, and anaplastic thyroid
carcinomas [7]. Non-overlapping mutations of the RET,
TRKA, RAS,a n dBRAF genes are found in PTCs.
Activating point mutations in the genes encoding RAS
small GTPases are found mainly in fvPTC [8]. Point
mutations in BRAF are the most common genetic lesions
in PTCs [9-12]. FTCs are characterized by RAS point
mutations [13] or by the PAX8/PPARg rearrangement
[14]. RAS point mutations can also be found in FAs [15].
In recent years, a number of studies that report the use of
several techniques of mutation detection in material
obtained by FNAC for the diagnosis of thyroid nodules
have been published [16,17]. These studies, taken
together, support the feasibility of testing the presence of
mutations in FNA samples and suggest that the presence
of these mutations could increase the diagnostic accuracy
for thyroid nodules. However, most of these studies are
retrospective, analyze BRAF status almost exclusively (and
RAS, RET/PTC,a n dPAX8/PPARg genetic alterations only
in some cases), and do not provide information regarding
the specificity and sensitivity of molecular analysis or its
diagnostic power in comparison with cytology.
Recent advances
Recently, some studies have shown that molecular
analysis of thyroid nodules can be applied in a clinical
setting and can improve the accuracy of the diagnosis. In a
large prospective study, Nikiforov and colleagues [18]
systematically analyzed 470 FNAs from 328 patients for a
panel of genetic alterations, including BRAF, RAS, RET/
PTC,a n dPAX8/PPARg mutations, and correlated these
results with cytology, surgical pathology, and clinical
follow-up. The presence of a mutation was a strong
indicator of malignancy, with a specificity of almost
100%. BRAF, RET/PTC,a n dPAX8/PPARg mutations were
always associated with carcinomas, whereas RAS muta-
tions were found in FA in a few cases, but never in
hyperplastic nodules. However, the sensitivity of mole-
cular testing was around 60%. Cytology was 100%
specific in identifying malignant lesions, but its sensitivity
was only 40%. Together, molecular analysis and cytology
reached 80% sensitivity. Thus, mutation screening was
able to identify malignant lesions that could not be
identified by cytology. A few cases carrying genetic
alterations have been identified in the cytology-negative
group, but most of the mutation-positive cases fell in the
group of indeterminate cytology. Thus, molecular analysis
is particularly helpful for this group. This concept is
further supported by another report, in which 513
indeterminate lesions (FLUSs) were specifically analyzed
[19]. For 117 of them, surgical pathology outcome was
available. Twenty of them were carcinomas, according to
pathological analysis. Molecular screening identified 12
cases positive for BRAF, RAS,o rPAX8/PPARg (no RET/
PTC mutations were found in this sample set), and all of
them were carcinomas, indicating that FLUSs with
positive molecular tests have a high probability of being
malignant. Similar findings were reported by Cantara and
colleagues [20]. These authors analyzed 235 FNA samples
for BRAF, RET, TRKA,an dPPARg mutations and found 67
genetic alterations. The same mutations were searched for
insurgicaltissuesamplesfromthesamepatients,inwhich
76 mutations were found. All of the mutations found in
cytological samples were also observed in the correspond-
ing tissue sample. Moreover, in the tissues, additional
mutations were found. Molecular analysis improved the
diagnostic performance of FNAC. Importantly, this report
also indicates that the molecular analysis is particularly
useful in samples with indeterminate or inadequate
cytology. Moreover, molecular analysis identified six
PTCs in the group with benign cytology [20].
In both reports, the authors analyzed the status of known
oncogenes in thyroid nodules and found that molecular
diagnosis could improve the diagnostic accuracy of
FNAC. However, some malignant lesions could not be
identified through this method. One possibility is that,
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accurate. Indeed, whereas DNA retrieval from FNA is
quite easy and reliable, RNA extraction from these
samples is more difficult, and good quality material
cannot always be obtained. This would impair the
detection of RET/PTC or PAX8/PPARg rearrangement in
particular. So it is possible that at least some rearrange-
ments are missed in this screening. This is indeed
confirmed by the report by Cantara et al. [20]. These
authors found more mutations in tissue samples than in
FNACs and suggest that the discrepancy between results
obtained from cytology and pathology samples was due
to technical reasons and was more frequent in the RET/
PTC-positive cases [20]. Another possibility is that some
thyroid carcinomas harbor rare mutations in known
oncogenes that were not searched for. Moreover, since
the RET/PTC-RAS-BRAF-ERK signaling pathway is rele-
vant for PTCs [21], it is possible that other mutations
may be found in novel genes that are effectors or
regulators of this signaling cascade. Alternatively, other
mutations could affect genes that belong to distinct
signaling pathways.
Taken together, these reports strongly indicate that the
molecular screening of FNA samples is feasible and
useful. A standardization of the techniques is urgently
needed in order for the results between the different
diagnostic centers to be comparable. polymerase chain
reaction on DNA and identification of mutations in
BRAF and RAS genes is a sensitive, specific, reliable, and
reproducible technique. However, the identification of
RET/PTC and PAX8/PPARg rearrangements is more
problematic and an amelioration of this technique or
the application of a novel method should be considered.
Moreover, the search for novel genes or markers of
malignancy should definitely be pursued.
Implications for clinical practice
These studies are very important for the clinical manage-
ment of thyroid nodules. They indicate that molecular
diagnosis is more powerful than cytology in identifying
true carcinomas and that, together with cytological
analysis, it can significantly improve the diagnostic
accuracy of thyroid nodules. This is particularly true for
lesions of indeterminate nature, which are the most
troublesome. In this set of lesions, the finding of a
mutation was almost always associated with malignancy.
This would indicate that patients who have undefined
cytology but who are positive for molecular tests should
undergo total thyroidectomy instead of repeated FNAs.
Patients who have a cytological diagnosis ‘suspicious for
malignancy’ and who also score positive on molecular
tests should directly undergo total thyroidectomy instead
of diagnostic lobectomy.
We think that not only indeterminate but also benign
and malignant FNAC samples should undergo molecular
analysis. Patients with indeterminate or benign cytology
will benefit from molecular tests because some malig-
nant cases not diagnosed with cytology will be identified
and cured. In patients with malignant cytology, mole-
cular analysis could improve the prognostic power of
FNAC and influence therapy by identifying the specific
mutation For instance, the presence of a BRAF mutation
is indicative of a worse prognosis and might suggest a
more radical treatment [22]. Moreover, the identification
of a BRAF mutation, but not a RET/PTC or RAS mutation,
predicts responsiveness to mitogen-activated protein
kinase kinase (MEK) inhibitors [21,23]. In the reports
discussed above, some cases that scored positive for RAS
mutation turned out to be FA, a benign lesion [18,20].
However, the authors suggest that precautional thyroi-
dectomy in these patients would be a reasonable choice
since RAS-positive FAs are considered precursors of PTC
or FTC and since RAS mutations are also associated with
a worse prognosis in thyroid cancer [24]. We agree with
this view and suggest that RAS-positive lesions be treated
with total thyroidectomy, irrespectively of the cytological
or pathological diagnosis.
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